Also trades as: BIT.AX (ASX) · $vol 0M
BITRF OTC
Biotron Limited
1W: +2666.7%
1M: +3092.3%
3M: +1975.0%
YTD: +266.3%
1Y: +219.2%
3Y: -15.3%
5Y: +80.4%
$0.02
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$19.4M
52W Range0.0011-0.10144
Volume1,000
Avg Volume119,669
Beta-0.64
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichelle Miller GCertAppFin
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2013-03-22
Websitebiotron.com.au
66 Hunter Street
Sydney, NSW 2000
AU
Sydney, NSW 2000
AU
61 2 9300 3344
About Biotron Limited
Biotron Limited is an Australian biotechnology firm focused on the development and market introduction of small-molecule compounds designed to combat various viral infections. The company's primary antiviral agent, BIT225, is currently undergoing Phase II clinical trials to assess its efficacy against SARS-CoV-2, HIV-1, and hepatitis C virus infections. Founded in 1999, Biotron Limited's main offices are situated in Sydney, Australia.
Latest News
No recent news
Recent Insider Trades
No insider trades found